Literature DB >> 21310583

A comparison of buprenorphine induction strategies: patient-centered home-based inductions versus standard-of-care office-based inductions.

Chinazo O Cunningham1, Angela Giovanniello, Xuan Li, Hillary V Kunins, Robert J Roose, Nancy L Sohler.   

Abstract

Although novel buprenorphine induction strategies are emerging, they have been inadequately studied. To examine our newly developed patient-centered home-based inductions, we conducted a subgroup analysis of 79 opioid-dependent individuals who had buprenorphine inductions at an urban community health center. Participants chose their induction strategy. Standard-of-care office-based inductions were physician driven, with multiple assessments, and observed, and the patient-centered home-based inductions emphasized patient self-management and included a "kit" for induction at home. We conducted interviews and extracted medical records. Using mixed nonlinear models, we examined associations between induction strategy and opioid use and any drug use. Compared with those with standard-of-care office-based inductions, participants with patient-centered home-based inductions had no significant differences in opioid use (adjusted odds ratio [AOR] = 0.63, 95% confidence interval [CI] = 0.13-2.97) but greater reductions in any drug use (AOR = 0.05, 95% CI = 0.01-0.37). Taking into account the limitations of our observational cohort study design, we conclude that participants with patient-centered home-based inductions had similar reductions in opioid use and greater reductions in any drug use than those with standard-of-care office-based inductions. It is essential that new induction strategies be based on existing models or theories and be well studied.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21310583      PMCID: PMC3081891          DOI: 10.1016/j.jsat.2010.12.002

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  29 in total

Review 1.  Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation.

Authors:  A T McLellan; D C Lewis; C P O'Brien; H D Kleber
Journal:  JAMA       Date:  2000-10-04       Impact factor: 56.272

2.  A controlled trial of buprenorphine treatment for opioid dependence.

Authors:  R E Johnson; J H Jaffe; P J Fudala
Journal:  JAMA       Date:  1992-05-27       Impact factor: 56.272

3.  Buprenorphine: a controlled clinical trial in the treatment of opioid dependence.

Authors:  P P Pani; I Maremmani; R Pirastu; A Tagliamonte; G L Gessa
Journal:  Drug Alcohol Depend       Date:  2000-07-01       Impact factor: 4.492

4.  Adolescent sexual behavior, drug use, and violence: increased reporting with computer survey technology.

Authors:  C F Turner; L Ku; S M Rogers; L D Lindberg; J H Pleck; F L Sonenstein
Journal:  Science       Date:  1998-05-08       Impact factor: 47.728

5.  A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence.

Authors:  W Ling; D R Wesson; C Charuvastra; C J Klett
Journal:  Arch Gen Psychiatry       Date:  1996-05

6.  A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence.

Authors:  R E Johnson; M A Chutuape; E C Strain; S L Walsh; M L Stitzer; G E Bigelow
Journal:  N Engl J Med       Date:  2000-11-02       Impact factor: 91.245

7.  Double-blind randomized trial of buprenorphine and methadone in opiate dependence.

Authors:  S Petitjean; R Stohler; J J Déglon; S Livoti; D Waldvogel; C Uehlinger; D Ladewig
Journal:  Drug Alcohol Depend       Date:  2001-03-01       Impact factor: 4.492

8.  Evaluation of buprenorphine maintenance treatment in a French cohort of HIV-infected injecting drug users.

Authors:  Maria-Patrizia Carrieri; D Rey; A Loundou; G Lepeu; A Sobel; Y Obadia
Journal:  Drug Alcohol Depend       Date:  2003-10-24       Impact factor: 4.492

9.  Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and addiction severity index.

Authors:  E C Strain; M L Stitzer; I A Liebson; G E Bigelow
Journal:  J Clin Psychopharmacol       Date:  1996-02       Impact factor: 3.153

10.  Buprenorphine treatment in an urban community health center: what to expect.

Authors:  Chinazo Cunningham; Angela Giovanniello; Galit Sacajiu; Susan Whitley; Pamela Mund; Robert Beil; Nancy Sohler
Journal:  Fam Med       Date:  2008 Jul-Aug       Impact factor: 1.756

View more
  18 in total

1.  Buprenorphine implant for opioid addiction.

Authors:  Walter Ling
Journal:  Pain Manag       Date:  2012-07

2.  Same-day vs. delayed buprenorphine prescribing and patient retention in an office-based buprenorphine treatment program.

Authors:  Andrea Jakubowski; Tiffany Lu; Frank DiRenno; Benjamin Jadow; Angela Giovanniello; Shadi Nahvi; Chinazo Cunningham; Aaron Fox
Journal:  J Subst Abuse Treat       Date:  2020-09-22

3.  Responding to the opioid and overdose crisis with innovative services: The recovery community center office-based opioid treatment (RCC-OBOT) model.

Authors:  Robert D Ashford; Austin M Brown; Jessica McDaniel; Jenna Neasbitt; Chad Sobora; Robert Riley; Lesley Weinstein; Aaron Laxton; Justin Kunzelman; Kyle Kampman; Brenda Curtis
Journal:  Addict Behav       Date:  2019-06-21       Impact factor: 3.913

4.  Self-management of buprenorphine/naloxone among online discussion board users.

Authors:  Shan-Estelle Brown; Frederick L Altice
Journal:  Subst Use Misuse       Date:  2014-06       Impact factor: 2.164

Review 5.  The New Kid on the Block--Incorporating Buprenorphine into a Medical Toxicology Practice.

Authors:  Timothy J Wiegand
Journal:  J Med Toxicol       Date:  2016-03

6.  Preferences for Aftercare Among Persons Seeking Short-Term Opioid Detoxification.

Authors:  Michael D Stein; Bradley J Anderson; Genie L Bailey
Journal:  J Subst Abuse Treat       Date:  2015-07-14

7.  Patterns, contexts, and motivations for polysubstance use among people who inject drugs in non-urban settings in the U.S. Northeast.

Authors:  Pablo K Valente; Angela R Bazzi; Ellen Childs; Peter Salhaney; Joel Earlywine; Jennifer Olson; Dea L Biancarelli; Brandon D L Marshall; Katie B Biello
Journal:  Int J Drug Policy       Date:  2020-09-07

8.  Integrating buprenorphine maintenance therapy into federally qualified health centers: real-world substance abuse treatment outcomes.

Authors:  Marwan S Haddad; Alexei Zelenev; Frederick L Altice
Journal:  Drug Alcohol Depend       Date:  2013-01-17       Impact factor: 4.492

9.  Use of a novel prescribing approach for the treatment of opioid use disorder: Buprenorphine/naloxone micro-dosing - a case series.

Authors:  Rupinder Brar; Nadia Fairbairn; Christy Sutherland; Seonaid Nolan
Journal:  Drug Alcohol Rev       Date:  2020-07

10.  Perceived relapse risk and desire for medication assisted treatment among persons seeking inpatient opiate detoxification.

Authors:  Genie L Bailey; Debra S Herman; Michael D Stein
Journal:  J Subst Abuse Treat       Date:  2013-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.